Department of Urology. University Hospital Grosshadern - Munich, Marchioninistr. 15, D-81377 München, Germany.

This email address is being protected from spam bots, you need Javascript enabled to view it

In the past three decades many efforts have been undertaken to understand the mechanisms of tumor angiogenesis. The introduction of anti-angiogenic drugs in tumor therapy during the last few years necessitates the establishment of new techniques enabling molecular imaging of tumor vascular remodelling. The determination of tumor size as commonly used is not appropriate since the extended necrosis under anti-angiogenic therapy does not necessarily result in the reduction of tumor diameter. The basis for the molecular imaging of tumor blood vessels is the remodelling of the tumor vessels under anti-angiogenic therapy which obviously occurs at an early stage and seems to be a convincing parameter. Beside the enormous progress in this field during the last few years the resolution is still not high enough to evaluate the remodelling of the micro tumor vessels. New imaging approaches combining specific molecular markers for tumor vessels with the different imaging techniques are needed to overcome this issue as exemplarily discussed for prostate cancer in this review. Molecular contrast agents targeting the vasculature will allow clinicians the visualization of vascular remodelling processes taking place under anti-angiogenic therapy and improve tumor diagnosis and follow-up.

Written by:
Tilki D, Seitz M, Singer BB, Irmak S, Stief CG, Reich O, Ergün S.   Are you the author?

Reference:
Anticancer Res. 2009 May;29(5):1823-9.

PubMed Abstract
PMID:19443411

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!